Subscribe To

Price Alert Latest News Economic Calendar News

NRXS / Medtech company NeurAxis upsizes IPO and lowers price to $6 a share vs. $8 previously

NeurAxis, a medical technology company with an FDA-approved therapy to treat abdominal pain associated with IBS in adolescents aged 11 to 18 years old, tweaked the terms of its initial public offering on Friday. In a filing with the Securities and Exchange Commission, the company said it now plans to offer 1.7 million shares priced at $6 each, while selling shareholders will offer 2.8 million shares. Read More

Demo Live Account See Partner Details

Content Topics

Medtech

Company

Neuraxis

Upsizes

Lowers

Price

Previously

Stock

NRXS

Posted: Jul 21 2023, 06:20

Author Name: Market Watch

NRXS News

By Market Watch
July 21, 2023

Medtech company NeurAxis upsizes IPO and lowers price to $6 a share vs. $8 previously

NeurAxis, a medical technology company with an FDA-approved therapy to treat abdominal pain associated with IBS in adolescents aged 11 to 18 years old

By Seeking Alpha
January 27, 2023

Neuraxis Seeks $15 Million IPO For Device Expansion

Neuraxis, Inc. has filed proposed terms for a $15 million U.S. IPO. The firm is developing neuromodulation technologies for the treatment of various p

By Seeking Alpha
January 12, 2023

Neuraxis Begins $33 Million U.S. IPO Effort

Neuraxis has filed to raise $33 million in a U.S. IPO, although the final figure may differ. The company is developing and commercializing neurostimul

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.